8-K: Processa Pharma Announces 1-for-25 Reverse Stock Split

Processa Pharmaceuticals, Inc. has filed a Certificate of Amendment to effect a 1-for-25 reverse stock split of its common stock, effective December 16, 2025.

Summary

• Processa Pharmaceuticals, Inc. (PCSA) filed a Certificate of Amendment to its Fourth Amended and Restated Certificate of Incorporation to implement a 1-for-25 reverse stock split.
• The reverse stock split will become effective at 5:00 p.m. Eastern Time on December 16, 2025.
• Beginning with the opening of trading on December 17, 2025, Processa's Common Stock will trade on the Nasdaq Capital Market on a split-adjusted basis under new CUSIP number 74275C403, continuing to use the symbol PCSA.
• Every twenty-five (25) shares of Common Stock issued and outstanding will be converted into one (1) share of Common Stock.
• Fractional shares will not be issued; stockholders who would otherwise receive fractional shares will have their share count rounded up to the nearest whole number, with no money paid for fractional shares.
• The reverse stock split will not reduce the number of authorized shares of Common Stock, which remains 1,000,000,000, nor will it change the par value of $0.0001 per share.
• The reverse stock split will affect all stockholders uniformly and will not alter any stockholder's ownership percentage, except for the impact of fractional share rounding.
• All outstanding options, warrants, restricted stock units, and similar securities entitling holders to receive or purchase shares of Common Stock will be adjusted as a result of the reverse stock split.

Sentiment

Score: 3

Explanation: A reverse stock split is generally viewed as a negative signal, often indicating a company's struggle to maintain its stock price and exchange listing. While it addresses a compliance issue, it doesn't fundamentally improve the company's underlying business or financial health. The rounding up of fractional shares is a minor positive for some shareholders, but the overall sentiment remains cautious due to the typical implications of such an action.

Positives

• The reverse stock split is a strategic move to increase the per-share trading price, which is often necessary to maintain compliance with minimum bid price requirements for listing on exchanges like Nasdaq.
• Stockholders who would otherwise be entitled to receive fractional shares will benefit from having their share count rounded up to the nearest whole number, rather than receiving cash for fractions.

Negatives

• Reverse stock splits are frequently perceived negatively by the market, as they can signal underlying financial challenges or a company's struggle to maintain a sufficient stock price.
• While the overall ownership percentage remains largely uniform, the rounding up of fractional shares could result in minor, non-proportional adjustments for some individual stockholders.

Risks

• The filing does not explicitly list risks, but a reverse stock split carries the implicit risk that it may not sustainably achieve its intended goal of increasing investor confidence or maintaining a higher stock price if the company's fundamental business performance does not improve.
• There is a risk that the stock price could decline again following the split, potentially leading to further non-compliance with exchange listing requirements in the future.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the mechanics and effective dates of the reverse stock split.

Management Comments

• The Board of Directors of the Corporation duly adopted a resolution pursuant to Section 242 of the DGCL setting forth a proposed amendment to the Certificate of Incorporation and declaring said amendment to be advisable.

Industry Context

Reverse stock splits are a common corporate action across various industries, including biotechnology and pharmaceuticals, typically undertaken by companies whose stock price has fallen below minimum exchange listing requirements. This action is generally a compliance measure rather than an indicator of specific industry trends or operational performance.

Comparison to Industry Standards

• Reverse stock splits are a standard mechanism employed by companies across diverse sectors, including biotech and pharma, to meet stock exchange listing criteria, such as Nasdaq's minimum bid price rule.
• Many small-cap biotechnology companies, facing similar challenges with low share prices, have executed comparable reverse splits (e.g., 1-for-10, 1-for-20, or 1-for-50) to regain compliance.
• The 1-for-25 ratio implemented by Processa Pharmaceuticals is within the typical range observed for companies aiming to significantly increase their per-share price to satisfy exchange requirements.

Corporate Governance

Stakeholder Impact

• Shareholders: Will hold fewer shares, but each share will have a proportionally higher price. Fractional shares will be rounded up to the nearest whole number. Overall ownership percentage remains largely the same, with minor adjustments due to rounding.
• Option/Warrant Holders: Their outstanding options, warrants, and similar securities will be adjusted in accordance with their terms to reflect the new share count and price.
• Nasdaq Capital Market: The action is intended to help the company maintain compliance with Nasdaq's minimum bid price requirement, potentially preventing delisting.

Next Steps

• The Company's common stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market on December 17, 2025.
• Outstanding options, warrants, restricted stock units, and similar securities will be adjusted to reflect the reverse stock split.

Key Dates

Recommendation

The reverse stock split is a technical corporate action primarily aimed at maintaining Nasdaq listing compliance by increasing the per-share price. It does not inherently reflect an improvement in the company's operational performance or financial health. While it addresses a critical technical issue, it does not provide a strong fundamental basis for a 'buy' recommendation, nor does it immediately warrant a 'sell' unless there are other negative fundamental indicators. A 'hold' recommendation is appropriate, allowing investors to observe if the company can leverage this structural change with improved business performance and financial results in the future.

Keywords

Processa Pharmaceuticals, PCSA, Reverse Stock Split, Stock Split, Nasdaq Capital Market, SEC Filing, 8-K, Corporate Action, Share Consolidation, Pharmaceuticals